A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT05006716
Trial Phases:	Phase I Phase II	Protocol IDs:	BGB-16673-101 (primary) NCI-2022-01959 2022-502157-33-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	BeOne Medicines
NCI Full Details:	http://clinicaltrials.gov/show/NCT05006716

Summary

Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1
monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety
expansion of selected doses, and a Phase 2 (expansion cohorts)

Objectives

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some
of our older studies were sponsored under the name BeiGene, you may see both names used
for this study on this website.

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

Georgia Cancer Center at Augusta University
1411 Laney Walker Boulevard
Augusta, GA 30912
www.augusta.edu/cancer/

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.